• FDA approves Novartis drug for bone marrow cancer Monday, 23 Feb 2015 | 3:58 PM ET

    WASHINGTON— Federal health officials have approved a new drug from Swiss drugmaker Novartis to treat a form of bone marrow cancer. The Food and Drug Administration said Monday it approved Farydak for patients with multiple myeloma, which causes the buildup of plasma cells in the bone marrow. However, after the meeting Novartis submitted additional...

  • Novartis' blood cancer drug wins U.S. approval Monday, 23 Feb 2015 | 3:18 PM ET

    Feb 23- The U.S. Food and Drug Administration approved Novartis AG's drug for treating a form of cancer that affects white blood cells. Multiple myeloma causes these cells to rapidly multiply and crowd out healthy blood cells from the bone marrow. The drug, Farydak, slows the multiplication of cells or causes them to die by blocking the activity of certain enzymes...

  • Feb 23- Rare disease drugmaker PTC Therapeutics Inc is exploring a potential sale amid takeover interest from several pharmaceutical companies, including Shire Plc and BioMarin Pharmaceutical Inc, according to people familiar with the matter. The stock of PTC Therapeutics, which has a market valuation of roughly $2 billion, rose as much as 25 percent to...

  • WASHINGTON, Feb 23- Novartis AG has won U.S. antitrust approval to buy GlaxoSmithKline's oncology drugs, with conditions, the U.S. Federal Trade Commission said on Monday. The deal is one of three related transactions announced in April 2014 in which GlaxoSmithKline would buy Novartis' global vaccine business, except for flu vaccines, Novartis would buy Glaxo's...

  • New hope for AIDS vaccine: Llamas? Monday, 23 Feb 2015 | 11:31 AM ET
    A Llama in Cusco, Peru

    Llamas appear to be immune to AIDS and HIV, giving scientists hope for developing a vaccine or treatment. Global Post reports.

  • NEW YORK— Bristol-Myers Squibb is using an acquisition that could be worth more than $1 billion and a separate collaboration agreement to continue its push into developing cancer treatments that use a patient's immune system to attack the disease. The New York drugmaker said Monday that it will buy the privately held biotechnology company Flexus for $800...

  • Feb 23- Eli Lilly and Co said it would delay its application to market its once-daily diabetes treatment, basal insulin peglispro, beyond the current quarter. The delay stems from a need to generate additional data to evaluate any potential effects on liver fat related to the treatment in late-stage trials, Lilly said. The company said it could not determine the...

  • Drugmaker Valeant to buy Salix: Sources Saturday, 21 Feb 2015 | 2:55 PM ET

    The all-cash deal could be announced as soon as Sunday, according to these sources who requested not to be identified.

  • BERLIN— The World Health Organization said Friday it has approved a quick test for Ebola that will dramatically cut the time it takes to determine— with reasonable accuracy— whether someone is infected with the deadly virus. The ReEBOV Antigen Rapid Test Kit, made by Colorado- based Corgenix, met sufficient quality, safety and performance requirements to allow...

  • Drug-resistant malaria spreads: Study Friday, 20 Feb 2015 | 7:41 AM ET
    File photo: A malaria victim rests at a small medical center in the Democratic Republic of Congo.

    The drug that has saved millions from malaria is losing its efficacy in a much larger swath of territory than was previously known. The NYT reports.

  • The U.S. private equity firm owns 80 percent of Panasonic Healthcare and Panasonic Corp owns 20 percent. Panasonic Healthcare, KKR and Bayer all declined to comment. Bloomberg reported on Thursday that a sale to Panasonic Healthcare, which could be valued at between 1 billion and 2 billion euros, could be announced as soon as Friday.

  • The Google Glass-enabled ambulance  Friday, 20 Feb 2015 | 6:21 AM ET

    NBC's Charlie Wojciechowski reports how Google Glass is helping save lives.

  • LOS ANGELES— An 18- year-old student is one of the seven people infected by a "superbug" outbreak tied to contaminated medical instruments at a Los Angeles hospital, and he is struggling to avoid becoming the third to die, his attorney said. The young man as spent nearly three months in the hospital and is in grave condition after being infected with a potentially...

  • The surprise announcement offers a path forward for Google- backed genetic testing firm 23 andMe, which previously clashed with regulators over its direct-to-consumer technology. In the same announcement, the FDA said it cleared the first carrier screening test from 23 andMe, which was forced to pull its health tests from the market in 2013 due to a lack of...

  • Stopping the Superbug  Thursday, 19 Feb 2015 | 1:11 PM ET

    A new antibiotic-resistant "Superbug" may have contributed to the deaths of 2 patients at Ronald Reagan-UCLA Medical Center. Discussing the threat, with Dr. William Schaffner, Professor of Preventive Medicine at Vanderbilt.

  • Nearly 170 may be exposed to 'nightmare bacteria' Thursday, 19 Feb 2015 | 8:10 AM ET

    Over 160 patients may have been exposed to a "superbug" between last October and January, the UCLA Health System said Wednesday.

  • Regeneron: Need fair drug prices  Thursday, 19 Feb 2015 | 7:38 AM ET

    Regeneron founder Dr. Leonard Schleifer, expresses the need to have a dialogue around the price of medicine.

  • LOS ANGELES— A "superbug" outbreak suspected in the deaths of two Los Angeles hospital patients is raising disturbing questions about the design of a hard-to-clean medical instrument used on more than half a million people in the U.S. every year. At least seven people— two of whom died— have been infected with a potentially lethal, antibiotic-resistant strain of...

  • Why 'Allergan' will live on after Activis takeover Wednesday, 18 Feb 2015 | 8:46 AM ET
    Actavis pharmaceuticals.

    Actavis can continue to perform while integrating Allergan into its business, CEO Brent Saunders tells CNBC.

  • Ron Klain, former U.S. Ebola czar, explains the safety and importance of vaccinating children to protect against measles.